These findings therefore complement the conclusion made

in the primary analysis of the clinical trial that the two-dose schedule was immunologically non-inferior to the three-dose schedule [6]. This study also supports the use of this simple modified ELISA approach to monitor avidities for vaccine and non-vaccine specific antibodies in future HPV vaccine studies. This work was funded by GlaxoSmithKline Biologicals SA. The costs associated with the development and publishing of the manuscript, including scientific writing assistance and statistical advice were also covered Lapatinib nmr by GlaxoSmithKline Biologicals SA. SG, LL, MB and CL developed and designed the study. LL, MB, CL and MF acquired the data. LL, MB, CL and MF performed and supervised the analysis. SG, LL, MB, CL, MF and FT were involved in the interpretation of the data. All authors were involved in the drafting of the manuscript or revising it critically for important intellectual content. All authors approved the manuscript before it was submitted by the corresponding author. All authors had full access to the data and had final responsibility to submit for publication. All authors completed the ICMJE Form for disclosure of potential conflicts of interest and declared that MEK inhibitor the following interests are relevant to the submitted work. All authors are employees

of the GlaxoSmithKline group of companies. Sandra Giannini, Clarisse Lorin and Florence Thomas report ownership of GSK stock options. The authors thank the study participants and their families, the study investigators and their staff members as well as the central and local teams of

GSK Vaccines for their participation in the clinical studies HPV-013 (NCT00196924), HPV-014 (NCT00196937), and HPV-048 (NCT00541970). Mehdi Hamrouni, Laurent Renquin and Annie Leroy (all GSK Vaccines) provided technical support. Frédéric Renaud (GSK Vaccines) and Marie-Pierre Malice (StatAdvice) performed the statistical analyses. Matthew Morgan (MG Science Communications) provided science and writing advice in the manuscript’s development. Ulrike Krause (GSK Vaccines) provided editorial advice and coordinated the manuscript’s development. “
“Influenza A viruses cause annual seasonal epidemics, sporadic avian influenza virus infections and influenza through pandemics such as the H1N1 pandemic virus of 2009–2010 [1]. Seasonal influenza A virus infections cause substantial mortality and morbidity, particularly in high risk groups, such as children younger than age 5, elderly, people with certain chronic medical conditions and immune-compromised individuals [2]. Active immunization is the most cost effective way of limiting influenza related morbidity and mortality. Current split-virion or subunit seasonal influenza vaccines, of which hemagglutinin (HA) is considered the major immunogenic component, are effective against circulating homologous virus strains [3].